FosA3 emerging in clinical carbapenemase-producing C. freundii
Frontiers in Cellular and Infection Microbiology · 2024
DOI: 10.3389/fcimb.2024.1447933 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2024. Verfasst von Vittoria Mattioni Marchetti und 5 weiteren Autor:innen. Beteiligte Einrichtung: Microbiology and Clinical Microbiology Unit, Scienze Clinico, Chirurgiche, Diagnostiche, Pediatriche (SCCDP) Department, University of Pavia, Pavia, …. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Bacterial Proteins, beta-Lactamases, Citrobacter freundii. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agentura Pro Zdravotnický Výzkum České Republiky, European Commission.
Abstract (Originalsprache)
Fosfomycin (FOS) is an effective antibiotic against multidrug-resistant Enterobacterales , but its effectiveness is reducing. Little is known on the current prevalence of FosA enzymes in low-risk pathogens, such as Citrobacter freundii . The aim of the study was the molecular characterization of a carbapenemase- and FosA-producing C. freundii collected in Italy. AK867, collected in 2023, showed an XDR profile, retaining susceptibility only to colistin. AK867 showed a FOS MIC >128 mg/L by ADM. Based on WGS, AK867 belonged to ST116 and owned a wide resistome, including fosA3 , bla KPC-2, and bla VIM-1. fosA3 was carried by a conjugative pKPC-CAV1312 plasmid of 320,480 bp, on a novel composite transposon (12,907 bp). FosA3 transposon shared similarities with other fosA3 -harboring pKPC-CAV1312 plasmids among Citrobacter spp. We report the first case of FosA3 production in clinical carbapenemase-producing C. freundii ST116. The incidence of FosA3 enzymes is increasing among Enterobacterales , affecting even low-virulence pathogens, as C. freundii .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Microbiology and Clinical Microbiology Unit, Scienze Clinico, Chirurgiche, Diagnostiche, Pediatriche (SCCDP) Department, University of Pavia, Pavia, Italy.
- Clinical Microbiology, Azienda Unità Sanitaria Locale (AUSL) Modena, Modena, Italy.
- Infectious Diseases Clinic, Azienda Ospedaliera Universitaria (AOU) Policlinico di Modena, Modena, Italy.
- I.R.C.C.S. Policlinico S. Matteo, Pavia, Italy.
- Department of Microbiology, Faculty of Medicine, University Hospital in Pilsen, Charles University, Pilsen, Czechia.
- Biomedical Center, Faculty of Medicine, Charles University, Pilsen, Czechia.
Förderung
- Agentura Pro Zdravotnický Výzkum České Republiky
- European Commission
Zitieren
APA
Mattioni Marchetti, V., Venturelli, I., Cassetti, T., Meschiari, M., Migliavacca, R., & Bitar, I. (2024). FosA3 emerging in clinical carbapenemase-producing C. freundii. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2024.1447933
Vancouver
Mattioni Marchetti V, Venturelli I, Cassetti T, Meschiari M, Migliavacca R, Bitar I. FosA3 emerging in clinical carbapenemase-producing C. freundii. Frontiers in Cellular and Infection Microbiology. 2024. doi:10.3389/fcimb.2024.1447933
BibTeX
@article{MattioniMarchetti2024,
author = {Mattioni Marchetti, Vittoria and Venturelli, Irene and Cassetti, Tiziana and Meschiari, Marianna and Migliavacca, Roberta and Bitar, Ibrahim},
title = {FosA3 emerging in clinical carbapenemase-producing C. freundii},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2024},
doi = {10.3389/fcimb.2024.1447933}
}
EUVIMED